Search results: Sage Journals

Restricted accessResearch articleFirst published February, 2004

Effects of Intravenous Amino Acid Administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher™]) Treatment

David Bushnell, Yusuf Menda, Thomas O'Dorisio [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2004

Radiolabeled RGD-DTPA-Tyr 3 -Octreotate for Receptor-Targeted Radionuclide Therapy

Bert Bernard, Astrid Capello, Martin van Hagen [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2008

Comparison of [ 177 Lu-DOTA 0,Tyr 3 ]-Octreotate and [ 177 Lu-DOTA 0,Tyr 3 ]-Octreotide for Receptor-Mediated Radiation Therapy of the Xenografted Human Midgut Carcinoid Tumor GOT1

Christina Swärd, Peter Bernhardt, Viktor Johanson [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2003

Assessment of Hepatic Toxicity from Treatment with 90 Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases

David Bushnell, Yusuf Menda, Mark Madsen [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2003

Tyr 3 -Octreotide and Tyr 3 -Octreotate Radiolabeled with 177 Lu or 90 Y: Peptide Receptor Radionuclide Therapy Results In Vitro

Astrid Capello, Eric P. Krenning, Wout A.P. Breeman [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2003

Biodistribution and Dosimetry of 177 Lu-Labeled [DOTA 0,Tyr 3 ]Octreotate in Male Nude Mice with Human Small Cell Lung Cancer

Anneli Schmitt, Peter Bernhardt, Ola Nilsson [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2007

Effects of Treatment with 177 Lu-DOTA-Tyr 3 -Octreotate on Uptake of Subsequent Injection in Carcinoid-Bearing Nude Mice

Peter Bernhardt, Jenny Oddstig, Lars Kölby [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2002

Octreotide and Octreotate Derivatives Radiolabeled with Yttrium: Pharmacokinetics in Rats

M. Laznicek, A. Laznickova, H. R. Mäcke [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2015

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study

Phillip G. Claringbold, J. Harvey Turner

Cancer Biotherapy and Radiopharmaceuticals

Open accessResearch articleFirst published September, 2014

Positron Emission Tomographic Imaging of Copper 64– and Gallium 68–Labeled Chelator Conjugates of the Somatostatin Agonist Tyr 3 -Octreotate

Jessie R. Nedrow, Alexander G. White, Jalpa Modi [...]

Molecular Imaging

Restricted accessResearch articleFirst published February, 2004

Effects of Intravenous Amino Acid Administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher™]) Treatment

David Bushnell, Yusuf Menda, Thomas O'Dorisio [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2004

Radiolabeled RGD-DTPA-Tyr 3 -Octreotate for Receptor-Targeted Radionuclide Therapy

Bert Bernard, Astrid Capello, Martin van Hagen [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2008

Comparison of [ 177 Lu-DOTA 0,Tyr 3 ]-Octreotate and [ 177 Lu-DOTA 0,Tyr 3 ]-Octreotide for Receptor-Mediated Radiation Therapy of the Xenografted Human Midgut Carcinoid Tumor GOT1

Christina Swärd, Peter Bernhardt, Viktor Johanson [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2003

Assessment of Hepatic Toxicity from Treatment with 90 Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases

David Bushnell, Yusuf Menda, Mark Madsen [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2003

Tyr 3 -Octreotide and Tyr 3 -Octreotate Radiolabeled with 177 Lu or 90 Y: Peptide Receptor Radionuclide Therapy Results In Vitro

Astrid Capello, Eric P. Krenning, Wout A.P. Breeman [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2003

Biodistribution and Dosimetry of 177 Lu-Labeled [DOTA 0,Tyr 3 ]Octreotate in Male Nude Mice with Human Small Cell Lung Cancer

Anneli Schmitt, Peter Bernhardt, Ola Nilsson [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2007

Effects of Treatment with 177 Lu-DOTA-Tyr 3 -Octreotate on Uptake of Subsequent Injection in Carcinoid-Bearing Nude Mice

Peter Bernhardt, Jenny Oddstig, Lars Kölby [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2002

Octreotide and Octreotate Derivatives Radiolabeled with Yttrium: Pharmacokinetics in Rats

M. Laznicek, A. Laznickova, H. R. Mäcke [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2015

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study

Phillip G. Claringbold, J. Harvey Turner

Cancer Biotherapy and Radiopharmaceuticals

Open accessResearch articleFirst published September, 2014

Positron Emission Tomographic Imaging of Copper 64– and Gallium 68–Labeled Chelator Conjugates of the Somatostatin Agonist Tyr 3 -Octreotate

Jessie R. Nedrow, Alexander G. White, Jalpa Modi [...]

Molecular Imaging